Abstract
Numerous epidemiological and experimental studies have established a strong connection between type 2 diabetes and the risk of the development of Alzheimer's disease. Indeed, several pathological features have been identified as common denominators of diabetic and Alzheimer's patients, including insulin resistance, dyslipidemia and inflammation, suggesting a close connection between the two disorders. Here we review common metabolic and inflammatory processes implicated in the pathogenesis of both disorders. In particular, the role of critical transcriptional checkpoints in the control of cellular metabolism, insulin sensitivity, and inflammation will be emphasized in this context. These transcriptional regulators hold great promise as new therapeutic targets in the potentially combined treatment of type 2 diabetes and Alzheimer's disease in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 787-808 |
| Number of pages | 22 |
| Journal | Journal of Alzheimer's Disease |
| Volume | 16 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2009 |
| Externally published | Yes |
Keywords
- Alzheimer's disease
- Energy homeostasis
- Insulin signaling
- Metabolic syndrome
- Transcription
- Type 2 diabetes
